Preventing Childhood Injury Safe Kids Worldwide is a global network of organizations whose mission is to prevent childhood injury. (See Prevention & Wellness.)
Engaging in Shared Interests (cont.)
WOMEN’S AND CHILDREN’S HEALTH
Saving and improving the lives of women and children is one focus of our philanthropic efforts. We have numerous community-based partnerships with groups such as UNICEF Safe Motherhood Initiative, the United Nations Population Fund Global Campaign to End Fistula and the European Child Safety Alliance. Many of these programs are outlined in the Our Giving section of www.jnj.com and in the 2009 Johnson & Johnson Contributions Report.
GLOBAL HEALTH COORDINATION
Pandemics highlight the complexity of managing global health. In October 2009, Johnson & Johnson entered into a strategic collaboration with Crucell, NV, focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The collaboration provides access to antibody and vaccine know-how and technology, and expands our ability to offer preventive health care solutions for unmet medical needs.
PREVENTION & WELLNESS
Johnson & Johnson is the founding sponsor of Safe Kids Worldwide, a global network of organizations whose mission is to prevent accidental childhood injury, a leading cause of death among children age 14 and under. Begun in 1987 by the Children’s National Medical Center, Safe Kids Worldwide is now in 16 countries with more than 450 coalitions, composed of health and safety experts, educators, corporations, foundations, governments and volunteers.
HEALTH CARE EDUCATION & DELIVERY
The UCLA/Johnson & Johnson Health Care Institute prepares Head Start personnel to teach parents of Head Start children to care for basic childhood illnesses. These parents, who are predominantly uninsured or utilize Medicaid to treat minor childhood illnesses, learn which problems they can care for at home and which require professional attention. The results are fewer lost schooldays or workdays and more effective care at a lower cost to the health care system.
DRUG TREATMENT & DEVELOPMENT
When it comes to finding the best scientific solutions for unmet medical needs, partnerships and collaborations are as important to us as investing in our own R&D pipelines. For example, Johnson & Johnson and Tianjin Medical University Cancer Hospital in China are partnering to collect and catalogue tumor specimens from patients. The effort will allow scientists to identify biomarkers that could help personalize medicine and advance cancer treatment. We’re also considering ways to use our R&D capabilities to address the needs of resource-poor countries (See Novel Partnerships Evolve Drug Development).
IMPROVING HEALTH CARE SYSTEMS
Johnson & Johnson supports health care reforms under way around the world and those voted on in the U.S. in early 2010 (See Working For Better Health Care Systems). But we also recognize that the business model for health care must change to meet growing global health care demands. We participate in PharmaFutures, an investor-led dialogue that explores how to better align corporate profitability with improved access to innovative and affordable health care. PharmaFutures 3, the most recent discussion, explored links between sustainable pharmaceutical business models and improved health outcomes in middle-income markets, including China, India and Brazil.